目的:确定三个新的用于测量游离甲溴芬素清除率的简化方程式是否给出了与Ekman等定义的方程式相似的结果。Al.,并评估所有四种方法的属性。区域甲溴芬清除率已用于预测区域肝脏治疗后的未来残余肝功能和肝功能衰竭,如部分肝切除。
方法:方法,标准偏差,在20例患者的连续26项研究中,比较了通过Ekman方法和三种简化方法测量的游离甲溴芬素清除率的相关性。比较血液和游离甲溴芬活性的分数变化,比较了正常血液和游离甲溴芬的积分(“有效时间”)。
结果:Ekman和第一,第二和第三简化方法为13.62±2.88%/min,12.98±2.97%/min,12.52±2.81%/min,15.03±2.27%/min,分别。新方法与Ekman的相关性分别为0.97、0.93和0.93。在测量间隔期间,血液和游离甲溴芬素活性的分数变化分别为0.381±0.065和0.329±0.062,差异0.052,P<0.5。正常血液和游离甲溴芬活性的积分分别为2.566±0.160min和2.661±0.158min,差异为0.094min,P<0.05。
结论:三种新方法的结果与Ekman方法相似。第一种简化方法被确定为在更大人群中进行临床验证的前导方法。
OBJECTIVE: To determine if three new simplified equations for measurement of free mebrofenin clearance give similar results to the equations defined by Ekman et. al ., and to evaluate the properties of all four methods. Regional mebrofenin clearance has been used to predict future remnant liver function and liver failure after regional liver therapy, such as partial hepatic resection.
METHODS: The means, standard deviations, and correlations of the free mebrofenin clearance measured by the Ekman method and the three simplified methods were compared in a consecutive series of 26 studies in 20 patients. The fractional change in the blood and free mebrofenin activities were compared, and integrals of normalized blood and free mebrofenin (\"effective times\") were compared.
RESULTS: The average percent free mebrofenin clearance for the Ekman and the first, second and third simplified methods were 13.62 ± 2.88%/min, 12.98 ± 2.97%/min, 12.52 ± 2.81%/min and 15.03 ± 2.27%/min, respectively. The correlations of the new methods with Ekman were 0.97, 0.93 and 0.93. The fractional changes during the measurement interval for the blood and free mebrofenin activities were 0.381 ± 0.065 and 0.329 ± 0.062, difference 0.052, P < 0.5. The integrals of normalized blood and free mebrofenin activities were 2.566 ± 0.160 min and 2.661 ± 0.158 min, difference of 0.094 min and P < 0.05.
CONCLUSIONS: The results of the three new methods were similar to the Ekman method. The first simplified method was identified as the lead method for clinical validation in a larger population.